Hikma Pharmaceuticals sustainability score: 46/100
Better than 59% of Healthcare / Pharmaceuticals
Leading practice starts at 60. The highest score on SINK is 71.
Hikma Pharmaceuticals is a London-listed maker of generic, injectable and branded medicines, with operations in North America, the Middle East and North Africa, and Europe. It reported $3,349 million of revenue for 2025, with about 9,600 employees.
Founded 2005Head office London, United KingdomStaff ~9,603 (2025)Revenue $3,349 million revenue (FY ended 31 Dec 2025, reported)Website ↗
Hikma publishes a full Scope 3 inventory (863,128 tCO2e in 2025, mostly purchased goods and services) and has reasonable assurance on its Scope 1 and 2, but its Scope 1 and 2 emissions rose in 2025 and Scope 3 rose slightly. Renewable electricity was 18% of its total, it has no Scope 3 or SBTi-validated target, and it has published no biodiversity assessment.
Hikma Pharmaceuticals scores 46/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Scores are free. Nobody can pay to change a score, speed it up or hide it. Last verified November 2026.
That places Hikma Pharmaceuticals joint 266th of 1,055 companies scored, and 10th of 23 in Healthcare / Pharmaceuticals.
What is Hikma Pharmaceuticals doing well, and where does it fall short?
Strongest on Carbon Footprint: Operations and Controversies & Red Flags (8/10, 8/10). Weakest on Nature & Biodiversity Impact and Emissions Trajectory (2/10, 3/10).
Where Hikma Pharmaceuticals lost points
For each question that lost points, the evidence our public rubric looks for that we didn't find.
What would raise this score
- Its effect on natureAssess its effect on nature and publish a basic environmental policy.
- Whether its emissions are fallingShow its emissions are falling.
- How it uses materials and handles wasteShow active waste reduction, reuse or repair.
Every question that lost points
- Emissions from its own operations8/10No verified figures published with their method and a falling trend.
- Emissions from its supply chain6/10No full value-chain map or supplier engagement programme.
- Whether its emissions are falling3/10No evidence its emissions are falling.
- How clean its energy is4/10Less than half its energy shown to be renewable, or no transition plan.
- Its effect on nature2/10No assessment of its effect on nature, and no basic environmental policy.
- How it uses materials and handles waste3/10No active waste reduction, reuse or repair shown.
- Its effect on water5/10No measured water footprint with reduction targets.
- Its climate targets4/10Its targets aren't science-based or committed to the Science Based Targets initiative.
- How openly it reports7/10No mission-locked structure, such as B Corp certification.
A score changes when the evidence does. We use new published evidence at the next rescore. Anyone can send us new evidence, free. How to send it.
How is Hikma Pharmaceuticals's SINK score calculated?
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleWhat evidence is Hikma Pharmaceuticals's score based on?
13 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
54% of them were published by Hikma Pharmaceuticals itself; the rest come from independent sources.
Hikma prints its 2025 Scope 1 and 2 (market-based, 127,983 tCO2e) and Scope 3 (863,128 tCO2e) totals separately; the total shown is their sum.
“A reasonable level of verification was conducted, aligned with the ISO 14064-3:2019 standard”
“In 2025, our Scope 1 and 2 emissions (market-based) measured 130,742 tonnes of carbon dioxide equivalent (tCO2e).”
“Total Scope 1 & 2 (market-based) 120,273”
“In 2025, we increased our solar energy generation in Hikma Salt, Jordan, which generates more than 4,700 MWh of electricity annually”
“From 2027, the VPPA will deliver approximately 40,000 MWh of renewable electricity to support Hikma’s European manufacturing operations.”
“announced that it has achieved B scores in both Climate Change and Water Security categories in the 2025 Carbon Disclosure Project (CDP) assessment”
“Hikma is committed to achieving Net Zero emissions by 2050 for its UK locations.”
“Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business.”
“Since 2021, the company has increased operational renewable energy capacity by 354 percent.”
“Hikma Pharmaceuticals and several attorneys general announced a $150 million agreement in principle”
“Purchase of goods and services 717,778 681,235 650,990”
“By 2028, we aim to implement key elements of the ISO 46001 Water Efficiency Management System across our MENA operations”
“The B score for Water Security represents a notable improvement over earlier reporting cycles”
If you believe a source has been misread or a newer version exists, submit a challenge.
Is this your company? Claim this profile (free)
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Send new evidence, free
Scored low because little is published? Publish what you do and send us the link, free. If it holds up, your score changes, and the change is logged on your page.
How to send evidence →Put your score on your website, free
It shows the current band, sector rank and score, and links to this page, so it changes when the score does.
Track this score
Bidding for a public contract? Check if you need a Carbon Reduction Plan, free →
Want your own page like this?
Free, independent, every source shown. Send it to any buyer who asks about your sustainability.
How does Hikma Pharmaceuticals compare with other healthcare / pharmaceuticals companies?
Where Hikma Pharmaceuticals sits among healthcare / pharmaceuticals peers.
Among the 23 major healthcare / pharmaceuticals brands we've scored, Hikma Pharmaceuticals sits 10th of 23.
Who scores higher in Healthcare / Pharmaceuticals?
The 3 companies in the sector scoring nearest above Hikma Pharmaceuticals.
Roche has achieved strong operational decarbonisation (46% S1&2 reduction since 2022) and received SBTi validation for net-zero targets — a pharma first.
See the breakdown →AstraZeneca has cut operational emissions 88% since 2015, but Scope 3 has risen 24% above baseline and now comprises 99% of total footprint.
See the breakdown →Sanofi's own emissions are 49% below 2019, but its total of 4.45 MtCO2e was flat in 2025 because its supply-chain emissions rose slightly.
See the breakdown →Which companies moved this week, and why.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
We'll send one email to confirm. No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
Find your page and claim it, free →Scores are free. Nobody can pay to change a score, speed it up or hide it.